Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Obesity and insulin resistance are positively correlated with plasma endothelin-1 (ET-1) levels; however, the mechanisms leading to increased ET-1 are not understood.
|
31147283 |
2019 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
The urinary CRP and 8-isoprostane significantly correlated with the obesity measures (body mass index, waist circumference, and waist-to- height ratio) and ET-1, inflammatory, and oxidative markers.
|
31737180 |
2019 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the mRNA expression of ET-1 was significantly increased in cultured HAECs in response to acute (< 24 h) and chronic (12-16 days) treatments with palmitic acid (PA), one of the most abundant saturated fatty acids in obesity.
|
29996135 |
2018 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Five hours of prolonged sitting, relative to regular interruptions to sitting time, impaired femoral artery vasodilator function and increased circulating ET-1 in overweight/obese adults.
|
30188800 |
2018 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Decreased ET-1 vasoconstriction is an important mechanism underlying the aerobic exercise-induced improvement in endothelium-dependent vasodilator function in overweight/obese adults.
|
28635124 |
2017 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observations and the identification of endothelin-1 as soluble mediator of the cardiovascular risk factor obesity may have relevant therapeutic implications.
|
28705795 |
2017 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
The combination of HFD and TET<sup>het</sup> overexpression increased the contractions of MRA and SRA to vasoconstrictors but not in the presence of meclofenamate; this combination also augmented further relaxations to isoproterenol in the A. Contractions to endothelin-1 in the IA were prevented by endothelin-A receptor antagonist BQ-123 but only attenuated in obese mice by BQ-788.
|
28216625 |
2017 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with central obesity have impaired insulin-stimulated vasodilation and increased ET-1 (endothelin 1) vasoconstriction, which may contribute to insulin resistance and vascular damage.
|
28289180 |
2017 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, during exercise, the ET-1 concentration at each step was significantly lower (p < 0.05) in the obese group.
|
28977804 |
2017 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transgenic expression of APPL1 prevented age- and obesity-induced impairment in insulin-induced vasodilation and reversed obesity-induced augmentation in insulin-evoked ET-1-dependent vasoconstriction.
|
21926268 |
2011 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
An increased effect of ET-1 could be a mechanism that contributes to increased basal lipolysis in human obesity.
|
18982011 |
2009 |
Obesity
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overweight/obese subjects (body mass index > or = 25 kg/m2) had 35% to 130% higher VECPE of NAD(P)H oxidase-p47(phox), nitrotyrosine, catalase, and the cytosolic antioxidant CuZn superoxide dismutase (all P < 0.05), as well as a 56% greater VECPE of the potent local vasoconstrictor endothelin-1 (P = 0.05) than normal-weight subjects (body mass index < 25 kg/m2).
|
17242275 |
2007 |
Obesity
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Another variant in the EDN1 gene in linkage disequilibrium with the Lys198Asn polymorphism may be responsible for the association with BP, or the interaction between the EDN1 Lys198Asn polymorphism and other factors such as obesity may be involved in the mechanisms elevating BP in vivo.
|
15198485 |
2004 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
The pathomechanisms underlying this ET-1 increase in obesity are poorly understood.
|
11934840 |
2002 |